Geode Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,142,444
| Closed | -$77.8M | – | 5075 |
|
|
2022
Q3 | $77.8M | Buy |
1,142,444
+58,608
| +5% | +$3.23M | 0.01% | 796 |
|
|
2022
Q2 | $34.6M | Sell |
1,083,836
-2,788
| -0.3% | -$81.6K | 0.01% | 1367 |
|
|
2022
Q1 | $37.6M | Buy |
1,086,624
+12,589
| +1% | +$376K | ﹤0.01% | 1451 |
|
|
2021
Q4 | $31.4M | Buy |
1,074,035
+11,430
| +1% | +$354K | ﹤0.01% | 1660 |
|
|
2021
Q3 | $27.1M | Sell |
1,062,605
-40,358
| -4% | -$1.19M | ﹤0.01% | 1748 |
|
|
2021
Q2 | $38.6M | Buy |
1,102,963
+333,240
| +43% | +$13M | 0.01% | 1526 |
|
|
2021
Q1 | $31.4M | Buy |
769,723
+17,993
| +2% | +$827K | ﹤0.01% | 1574 |
|
|
2020
Q4 | $32.6M | Buy |
751,730
+62,765
| +9% | +$3.09M | 0.01% | 1403 |
|
|
2020
Q3 | $38M | Sell |
688,965
-27,069
| -4% | -$1.72M | 0.01% | 1072 |
|
|
2020
Q2 | $45.2M | Sell |
716,034
-166,769
| -19% | -$11.4M | 0.01% | 950 |
|
|
2020
Q1 | $45.1M | Buy |
882,803
+61,459
| +7% | +$4.12M | 0.01% | 819 |
|
|
2019
Q4 | $65.3M | Buy |
821,344
+24,775
| +3% | +$1.47M | 0.01% | 790 |
|
|
2019
Q3 | $38.6M | Buy |
796,569
+63,646
| +9% | +$3.32M | 0.01% | 1031 |
|
|
2019
Q2 | $38.6M | Buy |
732,923
+55,226
| +8% | +$3.17M | 0.01% | 1037 |
|
|
2019
Q1 | $35.9M | Buy |
677,697
+57,967
| +9% | +$2.85M | 0.01% | 1029 |
|
|
2018
Q4 | $25.4M | Buy |
619,730
+83,347
| +16% | +$3.12M | 0.01% | 1115 |
|
|
2018
Q3 | $20.4M | Buy |
536,383
+30,238
| +6% | +$1.34M | 0.01% | 1404 |
|
|
2018
Q2 | $22.9M | Buy |
506,145
+86,358
| +21% | +$3.93M | 0.01% | 1258 |
|
|
2018
Q1 | $20.3M | Buy |
419,787
+78,836
| +23% | +$4.4M | 0.01% | 1251 |
|
|
2017
Q4 | $13.4M | Buy |
340,951
+7,875
| +2% | +$294K | ﹤0.01% | 1534 |
|
|
2017
Q3 | $10.3M | Buy |
333,076
+45,681
| +16% | +$1.28M | ﹤0.01% | 1697 |
|
|
2017
Q2 | $7.86M | Buy |
287,395
+42,728
| +17% | +$1.27M | ﹤0.01% | 1830 |
|
|
2017
Q1 | $9.02M | Buy |
244,667
+91,498
| +60% | +$2.3M | ﹤0.01% | 1689 |
|
|
2016
Q4 | $2.21M | Buy |
153,169
+18,702
| +14% | +$329K | ﹤0.01% | 2575 |
|
|
2016
Q3 | $3.1M | Buy |
134,467
+71,752
| +114% | +$1.37M | ﹤0.01% | 2277 |
|
|
2016
Q2 | $1.04M | Buy |
62,715
+9,282
| +17% | +$187K | ﹤0.01% | 2885 |
|
|
2016
Q1 | $847 | Buy |
53,433
+1,334
| +3% | +$23.7K | ﹤0.01% | 2971 |
|
|
2015
Q4 | $1.68M | Buy |
52,099
+10,748
| +26% | +$465K | ﹤0.01% | 2585 |
|
|
2015
Q3 | $1.74M | Buy |
+41,351
| New | +$1.95M | ﹤0.01% | 2532 |
|
Other funds holding GBT
Geode Capital Management's GBT Position: Q4 2022 in Review
Geode Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,142,444 shares — an estimated $77.8M sold.
Geode Capital Management first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $77.8M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Geode Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Geode Capital Management sold 1,142,444 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $77.8M.
- Geode Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Geode Capital Management's Global Blood Therapeutics, Inc. position peaked at $77.8M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.